Suicidality and Antidepressant Drugs
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of maprotiline or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Maprotiline is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for Patients and PRECAUTIONS: Pediatric Use.)
MAPROTILINE HYDROCHLORIDE TABLETS, USP
Maprotiline hydrochloride, USP is a tetracyclic antidepressant, available as 25 mg, 50 mg and 75 mg tablets for oral administration.
Maprotiline hydrochloride tablets are indicated for the treatment of depressive illness in patients with depressive neurosis (dysthymic disorder) and manic-depressive illness, depressed type (major depressive disorder). Maprotiline is also effective for the relief of anxiety associated with depression.
Media Articles Related to Maprotiline
Double Trouble: Depression Plus Diabetes Boosts Dementia Risk
Source: Medscape Psychiatry & Mental Health Headlines [2015.04.16]
Depression and diabetes raise the risk for dementia. Together they post the greatest risk, particularly in individuals younger than 65 years.
Medscape Medical News
Depression and diabetes combined may create even higher risk of cognitive decline
Source: Depression News From Medical News Today [2015.04.16]
Depression and diabetes each raised dementia risk on their own, but risk rose even more for people with both, in a large study of Alzheimer's disease and vascular dementia.
Depression Plus Diabetes May Boost Dementia Risk
Source: MedicineNet Dementia Specialty [2015.04.16]
Title: Depression Plus Diabetes May Boost Dementia Risk
Category: Health News
Created: 4/15/2015 12:00:00 AM
Last Editorial Review: 4/16/2015 12:00:00 AM
Antidepressant Washout Safe in Resistant Depression
Source: Medscape Psychiatry & Mental Health Headlines [2015.04.15]
Taking patients with treatment-resistant depression off antidepressant medication for a period in order to initiate a new antidepressant agent appears to be safe.
Medscape Medical News
Depression, Insomnia, Fatigue Are the Stuff of Nightmares
Source: MedicineNet Depression Specialty [2015.04.15]
Title: Depression, Insomnia, Fatigue Are the Stuff of Nightmares
Category: Health News
Created: 4/14/2015 12:00:00 AM
Last Editorial Review: 4/15/2015 12:00:00 AM
Published Studies Related to Maprotiline
Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males. [2007.11]
BACKGROUND: To investigate the effects of antidepressants on glucose-insulin homeostasis, we provided homogenous situation and performed standard procedures to assess the interactions of antidepressants and glucose regulation during hospitalization... CONCLUSIONS: The results suggest that the beta-cell function is hyperbolic in order to offset the insulin resistance following maprotiline treatment. Our findings imply that norepinephrine reuptake inhibitor (NRI) antidepressants might attenuate insulin sensitivity.
Clinical Trials Related to Maprotiline
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism [Recruiting]
Reduction of volume of the hippocampus has been associated with major depression in many
studies. It has been suggested that antidepressants may protect against hippocampus volume
loss in humans associated with multiple episodes of depression and may also reverse the
reduction of volume caused by the depression. In addition, genetic markers for serotonin are
implicated with depression, and may be an indication of reduced response to antidepressant
This study aims to enroll patients who are defined as having treatment resistant depression
(no remission after at least 2 treatments trials with an antidepressant). They will receive
an MRI scan at the initial visit and either 6 months after sustained remission or 12 months
after they enter the study for non-remitters. They will also be asked to give a blood sample
for genotyping. They will be matched by age and handedness to healthy volunteers with no
personal history of depression who will also receive an MRI scan and genotyping.
The first aim is to compare hippocampal volume of depressed subjects to healthy controls. It
is anticipated that subjects will initially have smaller hippocampal volume but of those who
sustain remission, there will be a small increase in hippocampal volume. It is also
anticipated that specific genetic markers will be related to individuals response to
Page last updated: 2015-04-16